Subjects n | 56 |
Male | 36 (64.3) |
Caucasian | 49 (87.5) |
Age at initiation of infliximab therapy years | 48.7±10.1 |
Disease duration at initiation of infliximab therapy years | 6.8±7.1 |
Diagnosis of sarcoidosis | |
Biopsy | 52 (92.9) |
Bronchoalveolar lavage | 3 (5.4) |
Clinical | 1 (1.8) |
Smoking status | |
Never-smokers | 27 (48.2) |
Current smokers | 4 (7.1) |
Former smokers | 25 (44.6) |
Scadding stage | |
0 | 5 (8.9) |
I | 6 (10.7) |
II | 16 (28.6) |
III | 14 (25.0) |
IV | 15 (26.8) |
Main treatment indication | |
Pulmonary | 34 (60.7) |
Cardiac | 2 (3.6) |
Small fibre neuropathy | 8 (14.3) |
Cutaneous | 4 (7.2) |
Central nervous system | 3 (5.4) |
Sinus | 1 (1.8) |
Myositis | 1 (1.8) |
Vocal cord paralysis | 1 (1.8) |
Ossal | 1 (1.8) |
Hypercalcaemia | 1 (1.8) |
Tertiary referral | 52 (92.9) |
Medication use prior to initiation of infliximab | |
Corticosteroids | 54 (96.4) |
Methotrexate | 51 (91.1) |
Azathioprine | 6 (10.7) |
Leflunomide | 1 (1.8) |
Plaquenil | 8 (14.3) |
Anti-TNF treatment | 13 (23.2) |
None | 0 (0) |
Use of ≥2 different drugs prior to infliximab | 52 (92.2) |
Concomitant medication | |
Corticosteroids | 24 (42.9) |
Methotrexate | 46 (82.1) |
Azathioprine | 4 (7.1) |
Leflunomide | 1 (1.8) |
None | 0 (0) |
Pulmonary function parameters | |
FVC L (% pred) | 3.32 (78.8) |
FEV1 L (% pred) | 2.30 (66.8) |
DLCOc L (% pred) | 6.01 (59.8) |
6MWD m (% pred) | 460.4 (62.2) |
Measurements of disease activity and severity | |
SUVmax lung parenchyma | 6.6±5.3 |
SUVmax mediastinum | 5.7±3.2 |
SUVmax total (including index localisation) | 9.0±5.2 |
ACE U·L−1 | 89.73±49.7 |
ACE Z-score | 4.26±4.8 |
sIL-2R pg·mL−1 | 8824±8503 |
Data are presented as n (%) or mean±sd, unless otherwise stated. TNF: tumour necrosis factor; FVC: forced vital capacity; % pred: % predicted; FEV1: forced expiratory volume in 1 s; DLCOc: diffusing capacity for carbon monoxide corrected for haemoglobin; 6MWD: 6-min walking distance; SUVmax: maximum standardised uptake value on 18F-fluorodeoxyglucose by positron emission tomography; ACE: angiotensin-converting enzyme; sIL-2R: soluble interleukin-2 receptor.